AIM2 and neoplasm: Interestingly, as mentioned above, it was highlighted that vaccination with AIM2-deficient DCs ameliorated adoptive T cell therapy and anti–PD-1 immunotherapy efficacy by promoting STING-induced type I IFN secretion, favoring CD8+ T cell infiltration through the production of CXCL10 while limiting the accumulation of T regs and the production of IL-1β and IL-18 production in response to tumor-derived DNA (Figure 3E) [4].